Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | CDK4 | P11802 | 9/20 | 0.48 |
| ▸ | CCND3 | P30281 | 7/20 | 0.48 |
| ▸ | CCND1 | P24385 | 6/20 | 0.48 |
| ▸ | CCND2 | P30279 | 6/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.48 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.48 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.48 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.47 |
| ▸ | CCNK | O75909 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355345 | 0.85 | EGFR (0.51) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL3571516 | 0.80 | EGFR (0.56) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL1355810 | 0.79 | CDK4 (0.60) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL269204 | 0.78 | EGFR (0.65) | EGFRCCND3CCNA2CDK2CCNK | |
| SCHEMBL264976 | 0.78 | CDK4 (0.54) | EGFRCDK4CCND3CCND1TTK | |
| Hydrochloric Acid SCHEMBL264469 | 0.78 | EGFR (0.64) | EGFRCCND3CCNA2CDK2CCNK | |
| SCHEMBL344015 | 0.77 | CDK4 (0.66) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL3579094 | 0.77 | CDK4 (0.50) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL1353948 | 0.76 | CDK4 (0.48) | EGFRCDK4CCND3CCND1CCND2 | |
| SCHEMBL1355286 | 0.75 | CDK4 (0.59) | EGFRCDK4CCND3CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EGFR 1291/4885CDK4 101/4885CCND3 196/4885 |
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | EGFR 1237/4885CDK4 102/4885CCND3 256/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EGFR 1291/4885CDK4 101/4885CCND3 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.